Danaher Co. (NYSE:DHR) Shares Purchased by Dai ichi Life Insurance Company Ltd

Dai ichi Life Insurance Company Ltd boosted its stake in shares of Danaher Co. (NYSE:DHR) by 4.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 51,913 shares of the conglomerate’s stock after buying an additional 2,000 shares during the quarter. Dai ichi Life Insurance Company Ltd’s holdings in Danaher were worth $14,433,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. CarsonAllaria Wealth Management Ltd. purchased a new position in shares of Danaher during the 2nd quarter worth approximately $25,000. nVerses Capital LLC purchased a new position in Danaher during the second quarter worth $25,000. MidAtlantic Capital Management Inc. purchased a new stake in shares of Danaher in the third quarter valued at $40,000. MFA Wealth Advisors LLC purchased a new stake in Danaher during the 2nd quarter worth about $51,000. Finally, Financial Connections Group Inc. acquired a new position in Danaher in the 2nd quarter valued at about $51,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Performance

Shares of DHR opened at $237.65 on Tuesday. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. Danaher Co. has a 12 month low of $215.68 and a 12 month high of $281.70. The firm has a fifty day simple moving average of $257.38 and a 200 day simple moving average of $259.93. The stock has a market capitalization of $171.65 billion, a price-to-earnings ratio of 45.35, a PEG ratio of 4.34 and a beta of 0.85.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The company’s revenue was up 3.1% on a year-over-year basis. During the same quarter last year, the company earned $2.02 EPS. Research analysts forecast that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were given a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. Danaher’s dividend payout ratio is currently 20.61%.

Analysts Set New Price Targets

DHR has been the subject of a number of research analyst reports. Robert W. Baird dropped their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Wells Fargo & Company assumed coverage on Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price objective for the company. Royal Bank of Canada reduced their price objective on Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. TD Cowen lifted their price target on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. Finally, Raymond James cut their target price on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $287.16.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.